Search for information about a product,
therapeutic area or event

Search

Media, investors, advocacy organizations and others, please contact us here.

Abstracts IgAN

Sparsentan as First-Line Treatment of Incident Patients with IgA Nephropathy: Preliminary Findings from the SPARTAN Trial

View
Posters

Long-Term Efficacy and Safety of Sparsentan in Young Patients WithFSGS: 240-Week Analysis of the DUET Open-Label Extension (OLE)

Learn More
Posters

Sparsentan Publications 2023

Learn More
Publications IgAN

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

View
Publications Nephrology

Effect of Multiple Doses of Sparsentan on the Single-Dose Pharmacokinetics of Dapagliflozin: An Open-Label Drug–Drug Interaction Study in Healthy Adults

View
Publications FSGS

Implications of Complete Proteinuria Remission at any Time in Focal Segmental Glomerulosclerosis: Sparsentan DUET Trial

View
Medical Information IgAN

SPARTAN (Phase 2 Study): Sparsentan as First-Line Therapy in the Treatment of IgA Nephropathy

Learn more
Medical Information IgAN

SPARTACUS (Phase 2 Study): Sparsentan in Combination With SGLT2 Inhibitors Study Design

Learn more
Medical Information FSGS

EPPIK (Phase 2 Study): Treatment in Pediatric Patients With Proteinuric Glomerular Diseases

Learn more
Medical Information IgAN

FILSPARI (sparsentan) – PROTECT (Phase 3 Study): Study Design & Results

Learn more
Medical Information FSGS

Phase 2 DUET Study Published in the Journal of the American Society of Nephrology

Learn more
Medical Information FSGS

FILSPARI (sparsentan) – Effect on Proteinuria in Focal Segmental Glomerulosclerosis

Learn more
Medical Information FSGS

FILSPARI (sparsentan) – Pediatric Patients in Sparsentan FSGS Studies

Learn more